Catalyst Wire Dossier Catalyst Wire Dossier

Beamion BCGC-1

· Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Beamion BCGC-1, covering 2026-04-15 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread [Phase 1, Phase 2]

See pricing